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S U M M A R Y
Objectives: To deﬁne local risk factors and outcomes for bacteremia with extended-spectrum beta-
lactamase-producing Enterobacteriaceae (ESBL-E) at a tertiary hospital in New Zealand.
Methods: Patients with ESBL-E bacteremia were compared to matched control patients with non-ESBL-
producing Enterobacteriaceae bacteremia. Patients were matched by onset of bacteremia (community vs.
hospital), site of blood culture collection (peripheral vs. via central line), and infecting organism species.
Results: Forty-four cases with matched controls were included. Eight- and 30-day mortality was higher
in cases than controls (27% vs. 7%; p = 0.011 and 34% vs. 11%, p = 0.011). Twenty-one cases (48%) were
community-onset. Community-onset cases were associated with urinary tract infection, whereas
hospital-onset cases were associated with central line infection, intensive care admission, and
Enterobacter cloacae. Independent risk factors for ESBL-E bacteremia were ﬂuoroquinolone exposure
(odds ratio (OR) 6.56, 95% conﬁdence interval (CI) 1.79–24), ﬁrst-generation cephalosporin exposure (OR
12.3, 95% CI 1.01–148), and previously-known colonization with ESBL-E (OR 46.2, 95% CI 3.45–619).
Conclusions: The association with ﬂuoroquinolone exposure suggests that measures to reduce
unnecessary use may be an effective preventative strategy. Known colonization with ESBL-E is a
strong risk factor for ESBL-E bacteremia, and colonization status should be taken into consideration
when choosing empirical therapy.
 2012 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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The incidence of bloodstream infections due to ESBL-producing
Enterobacteriaceae (ESBL-E) has increased worldwide during the
last 10 years.1 These infections have limited treatment options, and
when treated with inappropriate empirical therapy are associated
with increased mortality.2 Identiﬁcation of locally relevant risk
factors for such infections is therefore essential, both to guide
empirical therapy and to design rational preventative strategies.
Although numerous risk factors have been described in a variety of
geographic and epidemiological settings, few studies have
evaluated speciﬁc risk factors in the setting of a tertiary hospital
in Australasia. We performed a retrospective case–control study in* Corresponding author. Tel.: +64 9 367 0000; fax: +64 9 307 4939.
E-mail address: JoshuaF@adhb.govt.nz (J.T. Freeman).
1201-9712/$36.00 – see front matter  2012 International Society for Infectious Disea
doi:10.1016/j.ijid.2012.01.008order to identify risk factors and outcomes for bacteremia with
ESBL-E in patients admitted to Middlemore Hospital in Auckland,
New Zealand. The study protocol was approved by the local
institutional ethics committee.
2. Methods
Middlemore Hospital (MMH) is a 720-bed university-afﬁliated
tertiary hospital. With approval from the regional ethics commit-
tee, all patients admitted to MMH between May 1, 2003 and March
31, 2007 who had ESBL-E isolated from blood cultures were
identiﬁed using the Microbiology Laboratory database. Identiﬁca-
tion of bacterial isolates was performed using the Vitek 2 system
(BioMe´rieux). Conﬁrmatory testing for ESBL was performed using
the Clinical and Laboratory Standards Institute (CLSI) recommen-
dations,3 except for Enterobacter cloacae, which was conﬁrmed
using combination disk testing with cefepime and clavulanic acid.4ses. Published by Elsevier Ltd. All rights reserved.
Table 1
Comparison of patient characteristics between community-onset and hospital-onset cases
All ESBL-E bacteremia (n = 44)a Community-onset bacteremia (n = 21)a Hospital-onset bacteremia (n = 23) p-Valueb
Male gender 29 (66%) 15 (71%) 14 (61%) 0.54
Age 63.6 (18.2) 68.5 (17.3) 59.1 (18.3) 0.089
Residential care 6 (14%) 4 (19%) 2 (9%) 0.40
CVC 22 (50%) 4 (19%) 18 (78%) 0.0002
Long term urinary catheter 4 (9%) 3 (14%) 1 (4%) 0.335
Endotracheal tube 18 (41%) 1 (5%) 17 (74%) 0.0007
Inpatient days 51.0 (53.1) 59.0 (55.5) 43.7 (51.0) 0.35
Intensive care 15 (34%) 0 (0%) 15 (65%) <0.0001
Medical ward 26 (59%) 17 (81%) 9 (39%) 0.0065
General surgery ward 20 (45%) 9 (43%) 11 (48%) 0.77
Inpatient antibiotic days 29.4 (25.3) 29.1 (26.0) 29.7 (25.3) 0.95
Fluoroquinolone exposure 22 (50%) 9 (43%) 13 (57%) 0.55
Escherichia coli 16 (36%) 11 (52%) 5 (22%) 0.059
Klebsiella pneumoniae 18 (41%) 8 (38%) 10 (43%) 0.77
Enterobacter cloacae 9 (20%) 1 (5%) 8 (35%) 0.023
Enterobacter aerogenes 1 (2%) 1 (5%) 0 (0%) 0.48
Urinary tract source 15 (34%) 12 (57%) 3 (13%) 0.0036
CVC-related source 13 (30%) 1 (5%) 12 (52%) 0.0007
ESBL-E, extended-spectrum beta-lactamase-producing Enterobacteriaceae; CVC, central venous catheter.
a Categorical variables presented as absolute numbers and percentages, continuous variables as mean (standard deviation).
b Statistically signiﬁcant at p < 0.05.
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whose blood culture isolate was considered a contaminant by the
clinical team were excluded. Matched control patients with
bacteremia due to non-ESBL-producing Enterobacteriaceae were
also identiﬁed using the laboratory database. Control patients were
matched one to one with cases for the following characteristics: (1)
species of organism, (2) type of blood culture (peripheral culture or
central venous catheter culture), and (3) timing of bacteremia
relative to hospital admission (‘community-onset’ bacteremia was
deﬁned as bacteremia within 48 h of hospital admission, and
‘hospital-onset’ bacteremia was deﬁned as bacteremia occurring
>48 h after admission). Control patients were those whose
bacteremia was temporally closest to their matched case and
who had not been used as a control for another case. The following
data were collected from the clinical records: demographic data
(age, gender, and residential care facility residency), service
providing care, comorbidity (diabetes, chronic renal failure, renal
replacement therapy, and burn injury), clinical features (known
colonization with ESBL-E and source of bacteremia as determined
by managing team), healthcare exposures (timing, location, and
duration of hospital admissions, inpatient antibiotic use during the
12 months prior to bacteremia, surgical procedures, and presence
of invasive medical devices during the admission prior to the
bacteremia), and all-cause mortality at 8 and 30 days.
The statistical analysis was performed using SAS v9.2 (SAS
Institute Inc., Cary, NC, USA). Fisher’s exact test was used for the
analysis of 2  2 contingency tables and the Student’s t-test for the
comparison of means. Univariate and multivariate logistic regres-
sion (stepwise regression) analyses were used to compare matched
cases and controls. With the exception of mortality, variables
found to be signiﬁcant on univariate analysis were included in the
multivariate model. Statistically signiﬁcant differences wereTable 2
Mortality associated with bacteremia
8-day mortality 
Species ESBL-E case Non-ESBL-E control 
Escherichia coli 50% (8/16) 6% (1/16) 
Klebsiella pneumoniae 22% (4/18) 6% (1/18) 
Enterobacter spp 0% (0/10) 10% (1/10) 
Total 27% (12/44) 7% (3/44) 
ESBL-E, extended-spectrum beta-lactamase-producing Enterobacteriaceae.
a Statistically signiﬁcant at p < 0.05.deﬁned as a p-value of 0.05. All p- and t-values were two-tailed.
Study size was not pre-speciﬁed due to the limited numbers of
available cases and controls.
3. Results
A total of 45 patients had at least one positive blood culture
with ESBL-E during the study period. One patient was excluded
because their isolate was considered a contaminant, leaving 44
cases included. The characteristics of case patients are shown in
Table 1. Cases and controls were not signiﬁcantly different in
gender and age. The ethnic composition of the case and control
groups was also similar: 21 New Zealand Europeans in each group;
nine vs. ﬁve Maori and 11 vs. 15 Paciﬁc Islanders for cases and
controls, respectively.
Nearly half of the cases (48%; 21/44) had community-onset
bacteremia. Cases with community-onset bacteremia were not
signiﬁcantly different from hospital-onset cases with respect to
gender, age, or domicile in a residential care facility (Table 1).
However, community-onset cases were more likely to have a
urinary source of infection (12/21 vs. 3/23; p = 0.0036), whereas
hospital-onset cases were more likely to have E. cloacae bacteremia
(1/21 vs. 8/23; p = 0.023) and to have a central venous catheter
infection source (1/21 vs. 12/23; p = 0.0007). Hospital-onset ESBL-
E bacteremia occurred a median of 10 days after admission (range
3–57 days).
Mortality outcomes are shown in Table 2. Mortality rates
associated with ESBL-E bacteremia were 27% at 8 days (95%
conﬁdence interval (CI) 16–42%) and 34% at 30 days (95% CI 22–
49%). These rates were signiﬁcantly higher than rates in the control
group at both 8 days (12/44 vs. 3/44; p = 0.0112) and 30 days (15/
44 vs. 5/44; p = 0.0114). When stratiﬁed by species, no signiﬁcant30-day mortality
p-Valuea ESBL-E case Non-ESBL-E control p-Valuea
0.0155 63% (10/16) 13% (2/16) 0.0091
0.3377 28% (5/18) 11% (2/18) 0.40
1.0000 0% (0/10) 10% (1/10) 1.00
0.0112 34% (15/44) 11% (5/44) 0.011
Table 3
Univariate analysis comparing cases and controls with respect to putative risk
factors
ESBL-E
bacteremia
cases (n = 44)a
Non-ESBL-E
bacteremia
controls (n = 44)a
p-Valueb
Male gender 29 (66%) 21 (48%) 0.13
Age 64 (18) 59 (19) 0.25
Residential care 6 (14%) 2 (5%) 0.27
Central line 22 (50%) 14 (32%) 0.13
Endotracheal tube 18 (41%) 13 (30%) 0.37
Long-term urinary catheter 4 (9%) 2 (5%) 0.68
Temporary urinary catheter 20 (45%) 19 (43%) 1.0
Known ESBL-E colonization 16 (36%) 1 (2%) <0.0001
Total inpatient days medical 11.0 (13.4) 4.3 (8.1) 0.0053
Total inpatient days surgical 8.6 (16) 9.9 (27) 0.39
Total inpatient days 51.0 (53.1) 20.1 (28.1) 0.0011
Hemodialysis 9 (20%) 2 (5%) 0.0075
Diabetes 16 (36%) 12 (27%) 0.49
Urinary tract infection 13 (30%) 3 (7%) 0.066
Quinolone exposure 22 (50%) 7 (16%) 0.0007
Metronidazole exposure 16 (36%) 5 (11%) 0.0062
First-generation cephalosporin 10 (23%) 1 (2%) 0.014
Second-generation cephalosporin 28 (64%) 10 (23%) 0.0001
Third-generation cephalosporin 13 (30%) 4 (9%) 0.016
Total antibiotic days 29.4 (25.3) 15.9 (28.8) 0.022
ESBL-E, extended-spectrum beta-lactamase-producing Enterobacteriaceae.
a Categorical variables presented as absolute numbers and percentages,
continuous variables as mean (standard deviation).
b Statistically signiﬁcant at p < 0.05.
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Klebsiella pneumoniae and Enterobacter species cases, whereas
Escherichia coli bacteremia had a higher mortality rate in cases than
in controls. Cases with E. coli bacteremia were also different from
controls with respect to time in hospital during the preceding year
(mean 68 bed-nights for cases vs. 12 bed-nights for controls
p = 0.0019) and inpatient exposure to antibiotics (mean 30 days vs.
6 days; p = 0.0060).
In order to determine risk factors for ESBL-E bacteremia, cases
were compared to controls with respect to a number of putative
risk factors for ESBL-E bacteremia. On univariate analysis, cases
were signiﬁcantly more likely to be known to be colonized with
ESBL-E prior to their bacteremia and had a signiﬁcantly higher
mean number of days as an inpatient during the preceding year.
Cases also had greater exposure to antimicrobial agents in general
and to a number of speciﬁc antimicrobial classes (including ﬁrst-,
second-, and third-generation cephalosporins, ﬂuoroquinolones,
and metronidazole) during the 12 months prior to their bacteremia
(Table 3).
Multivariate analysis included all variables found to be
statistically signiﬁcant on the univariate analysis except mortality
(Table 4). Known colonization with an ESBL-E (odds ratio (OR)
46.2), exposure to ﬁrst-generation cephalosporins (OR 12.3), and
exposure to ﬂuoroquinolones (OR 6.56) were found to be
independently associated with ESBL-E bacteremia, as was total
inpatient days (OR 1.033 per admission day); admission underTable 4
Odds ratios for independent risk factors on multivariate analysis comparing cases of E
Risk factor 
Known colonization with an ESBL-producing organism 
Exposure to ﬁrst-generation cephalosporins within preceding 12 months 
Exposure to quinolone antibiotics within preceding 12 months 
Total inpatient days within preceding 12 months 
Days admitted under general surgery within preceding 12 months 
ESBL-E, extended-spectrum beta-lactamase-producing Enterobacteriaceae; OR, odds rat
a Statistically signiﬁcant at p < 0.05.
b Odds ratios for continuous variables are per unit of increment, i.e., per day of admgeneral surgery was found to be protective (OR 0.95 per inpatient
day).
An additional multivariate analysis was also performed on the
subgroup of 22 patients with ‘hospital-onset’ bacteremia. In this
subgroup, ﬂuoroquinolone use and known colonization remained
signiﬁcant with ORs of 7.0 (95% CI 1.4–34.6, p = 0.014) and 13.9
(95% CI 1.4–133.6, p = 0.02), respectively. For this subgroup of
patients, 13 were exposed to ﬂuoroquinolones during the
preceding year, 4/13 (31%) during the same admission as their
bacteremia, and 9/22 (41%) during admissions within the prior 6
months. Thirty of 44 (68%) ESBL isolates were resistant to
ciproﬂoxacin using the CLSI interpretive criteria.
4. Discussion
In our study, cases of ESBL-E bacteremia were associated with
higher all-cause mortality than non-ESBL-E controls at both 8 and
30 days. A number of factors may have contributed to this
observation. It is likely that this ﬁnding is at least partially
explained by intrinsic differences in comorbidity between cases
and controls. Nonetheless, the high mortality that we observed
highlights the frequently poor prognosis associated with ESBL-E
bacteremia and the importance of deﬁning clinical risk factors for
such infections.
Notably, nearly half of all cases in our study presented to the
hospital with their infection from the community. However, all but
one of the community-onset cases had been admitted to hospital at
some stage during the previous year; 52% (11/21) had invasive
medical devices in situ and a further 10% (2/21) were receiving
regular dialysis. These ﬁndings suggest that although these
patients had community-onset infections, many of these patients
may have acquired their ESBL-E during a previous hospital
admission. Only one patient (a previously healthy 21-year-old
Maori female who presented in 2005 with ESBL-E pyelonephritis)
appeared to have no comorbidities or previous healthcare
exposure. Importantly, the absence of healthcare exposure in this
patient suggests that acquisition of uropathogenic strains of ESBL-
producing E. coli is to some extent occurring in the community in
New Zealand. Similar reports of community spread of ESBL-
producing E. coli have been made in Spain, Canada, and the UK.5–7
In contrast to community-onset cases, hospital-onset cases
were less likely to have a urinary tract infection, but more likely to
have been previously admitted to the intensive care unit, to have
bacteremia due to E. cloacae, and to have a central venous catheter
source of infection. These differences are likely to reﬂect intrinsic
differences in epidemiology between different species of ESBL-E. E.
coli for example, has a particular propensity to cause urinary tract
infections in non-hospitalized patients compared to E. cloacae and
K. pneumoniae.8
Despite these differences within the case group, our study
identiﬁed several overarching risk factors for ESBL-E bacteremia.
ESBL-E bacteremia was highly associated with known colonization
with ESBL-E (OR 46.2). Nine of 16 cases with known colonization
had ESBL-E previously isolated from a clinical specimen and theSBL-E bacteremia with matched non-ESBL-E bacteremia controls
OR (95% CI) p-Valuea
46.2 (3.45–619) <0.0001
12.3 (1.01–148) 0.049
6.56 (1.79–24) 0.0066
1.033 (1.001–1.066)b 0.0017
0.95 (0.9–0.99)b 0.0019
io; CI, conﬁdence interval.
ission.
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of the hospital’s ESBL-E surveillance policy. Our ﬁndings therefore
support the intuitive notion that previous colonization or infection
with ESBL-E increases the probability of subsequent ESBL-E
bacteremia. A similar ﬁnding was reported in a case–control
study performed in Israel, where patients colonized with ESBL-E on
admission were found to be 39 times more likely than controls to
develop bacteremia during their hospital stay.9 Awareness of a
patient’s colonization status may therefore be useful, not only for
preventing hospital transmission of these organisms, but also for
guiding empirical therapy at the individual patient level.
Fluoroquinolone and ﬁrst-generation cephalosporin exposure
were found to be independently associated with ESBL-E bacter-
emia. Series in other geographic settings have also described
ﬂuoroquinolone use as an independent risk factor for ESBL-E
bacteremia.10,11 Fluoroquinolone-resistant, urovirulent clones
such as ST-131 E. coli have disseminated internationally in
association with ESBL production.12 In settings where ﬂuoroquin-
olone-resistant ESBL-E are prevalent, ﬂuoroquinolones will exert
selective pressure on the gut ﬂora that will favor ESBL-E
proliferation and infection in susceptible patients.13 Moreover, it
is possible that ﬂuoroquinolone use increases vulnerability for
acquisition of ﬂuoroquinolone-resistant organisms in non-colo-
nized patients.14 It seems likely therefore that measures to reduce
unnecessary ﬂuoroquinolone use could lead to decreased rates of
ESBL-E bacteremia.
Although the cephalosporins as a class have been repeatedly
associated with ESBL-E bacteremia in numerous studies, the
particular association with ﬁrst-generation cephalosporins that we
observed is an unusual ﬁnding. This ﬁnding may be explained by
the fact that in our hospital these agents are used in orthopedic
wards as surgical prophylaxis, and the orthopedic wards were sites
of documented ESBL-E cross-transmission during the study period.
Nonetheless, the association between ﬁrst-generation cephalos-
porins and ESBL-E bacteremia suggests that amongst cephalospor-
ins it is not solely third-generation agents that exert selective
pressure for ESBL-E.
This study has several limitations. Firstly, whilst the study had
adequate power to detect large differences between cases and
controls, the ability to detect small differences between the groups
was limited. Secondly, the cases were heterogeneous with respect
to timing of bacteremia onset. Also, our examination of antimicro-
bial use did not account for community use, or for concurrent use
of multiple agents.
Despite these limitations, our study is to our knowledge, the
ﬁrst to describe risk factors and outcomes for ESBL-E bacteremia in
the setting of a tertiary hospital in New Zealand. Moreover, we
identiﬁed several risk factors that deserve further attention. The
strong association between ESBL-E bacteremia and previous
colonization suggests that systematic screening for ESBL-E
colonization may provide useful information to guide empirical
therapy in high-risk patient groups. This concept is importantbecause inappropriate empirical therapy has been associated with
increased mortality. Also, our ﬁndings suggest that reduction of
unnecessary use of ﬂuoroquinolones and cephalosporins may be a
useful strategy to help reduce the incidence of ESBL-E bacteremia.
Further prospective studies to evaluate ESBL-E screening and
antimicrobial stewardship programs are warranted. The impor-
tance of such strategies will increase as the incidence of ESBL-E
bacteremia continues to increase in New Zealand hospitals.
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